Shanghai, China– 17th-18th October, 2015- Personalized medicine and genomics company, AKESOgen, attended and spoke at the third annual International Conference on Biomarkers Discovery and Clinical Application (ICB) in Shanghai, China as an industry expert on genomic profiling in multiple cancers. The ICB brought together international pharmaceutical, biotech and diagnostics companies, leading universities and institutions, healthcare, government, and national labs, CROs and tool providers. The third annual ICB focussed on the following:
- Trends in Biomarker Research
- Biomarkers and translational medicine
- Biomarkers in drug development
- Innovation in biomarker discovery
“International conferences such as the ICB marks the impact that genomic information, shared internationally, can provide to improving precision medicine” said Mark Bouzyk, CSO of AKESOgen.
About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.
Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or email@example.comShare this